To confirm these observations, we analyzed publically available data from the TCGA breast invasive carcinoma cohort.19 We find that PRMT5 is overexpressed in breast cancers—encompassing all subtypes—compared to normal breast tissues (data not shown), as previously reported.25 In contrast with the Curie cohort, the TCGA data shows no difference in PRMT5 mRNA expression between TNBC and HER2+ breast cancers (Figure 1A, right panel). Here, PRMT5 is linked to breast carcinoma.